| Cash Flow | 2026-04-30 |
|---|---|
| Net income (loss) | -37,304 |
| Interest expenses | 0 |
| Share-based compensation | 179,400 |
| Deferred tax assets | -16,038 |
| Bad debt expense | 61,366 |
| Inventories | 61,366 |
| Accounts receivable | -478,842 |
| Advance to vendor | -158,802 |
| Other current assets | -2,491 |
| Accounts payable | 208,813 |
| Accrued expenses and other current liabilities | 18,074 |
| Income tax payable | -178,673 |
| Net cash provided by operating activities | 814,407 |
| Repayment to related parties | 0 |
| Net cash used in financing activities | 0 |
| Net change in cash | 814,407 |
| Cash, beginning of year | 782,810 |
| Cash, end of year | 1,597,217 |
VitaNova Life Sciences Corp (VNOV)
VitaNova Life Sciences Corp (VNOV)